Clinical Trial Update: Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of Age [Phase 3]

View source ↗

Summary

Phase 3 study evaluating immunogenicity, safety, and tolerability of a fully liquid pentavalent vaccine (DTwP-Hib-HepB) in infants aged 6-8 weeks; the trial has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diphtheria
• Haemophilus Influenzae Type Infection
• Hepatitis B
• Pertussis
• Tetanus

Drugs mentioned

• Pentavalent DTwP-Hib-HepB vaccine (diphtheria-tetanus-pertussis-hepatitis B-haemophilus influenzae type b vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Diphtheria, Tetanus | Phase 3 | Status: COMPLETED